Business Context and Reporting Period
Oruka Therapeutics, Inc. (ORKA) filed a Form 8-K on April 27, 2026, to disclose the announcement of results from its Phase 2a EVERLAST-A clinical trial. The company is a biopharmaceutical firm developing ORKA-001, a potentially best-in-class anti-IL-23 antibody for the treatment of moderate-to-severe psoriasis (PsO).
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on clinical trial results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
The primary material event is the successful completion of the primary endpoint in the EVERLAST-A Phase 2a trial at Week 16. Key findings include:
- Primary Endpoint (PASI 100): 63.5% (40/63) of ORKA-001 treated patients achieved complete skin clearance compared to 4.8% (1/21) for placebo (p < 0.0001).
- Secondary Endpoints:
- IGA 0: 63.5% vs. 4.8% placebo.
- PASI 90: 82.5% vs. 4.8% placebo.
- IGA 0/1: 84.1% vs. 4.8% placebo.
- Safety Profile: Treatment-emergent adverse events (TEAEs) occurred in 50.8% of treated patients vs. 57.1% in placebo. No serious TEAEs or discontinuations due to adverse events were reported in the treatment arm. The most common TEAE was upper respiratory tract infection (19.0%).
- Phase 1 Data Update: Following a single 600 mg dose, drug concentrations remained above effective trough levels for 52 weeks, supporting the potential for annual dosing.
Guidance, Outlook, and Risks
Outlook and Future Trials:
- EVERLAST-A: The trial is ongoing; longer-term data on durability and safety are expected in the second half of 2026.
- EVERLAST-B: A Phase 2b dose-ranging trial is currently enrolling approximately 160 patients to evaluate three dose levels. Data is expected in 2027. This trial aims to confirm yearly dosing potential and extended off-treatment remissions.
Risks and Contingencies:
- The filing contains forward-looking statements regarding clinical trial timing, regulatory pathways, and the potential clinical profile of ORKA-001.
- Actual results may differ materially due to risks outlined in the company's most recent Form 10-K, including uncertainties in clinical development and regulatory approval.
Investor Verification Checklist
- Verify the statistical significance and clinical relevance of the PASI 100 and IGA 0/1 results in the full data presentation (Exhibit 99.2).
- Confirm the enrollment status and timeline for the EVERLAST-B Phase 2b trial.
- Review the company's cash runway and burn rate in the most recent 10-K or 10-Q, as this 8-K does not provide liquidity data.
- Monitor the second-half 2026 data readout for EVERLAST-A regarding durability of response.